GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cancer Genetics Inc (NAS:CGIX) » Definitions » Net Margin %

Cancer Genetics (Cancer Genetics) Net Margin % : -287.49% (As of Dec. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Cancer Genetics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Cancer Genetics's Net Income for the three months ended in Dec. 2020 was $-3.77 Mil. Cancer Genetics's Revenue for the three months ended in Dec. 2020 was $1.31 Mil. Therefore, Cancer Genetics's net margin for the quarter that ended in Dec. 2020 was -287.49%.

The historical rank and industry rank for Cancer Genetics's Net Margin % or its related term are showing as below:


CGIX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -156.25
* Ranked among companies with meaningful Net Margin % only.

Cancer Genetics Net Margin % Historical Data

The historical data trend for Cancer Genetics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Genetics Net Margin % Chart

Cancer Genetics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -58.42 -71.70 -413.08 -91.83 -139.12

Cancer Genetics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.51 -82.68 -117.57 -86.29 -287.49

Competitive Comparison of Cancer Genetics's Net Margin %

For the Biotechnology subindustry, Cancer Genetics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cancer Genetics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cancer Genetics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Cancer Genetics's Net Margin % falls into.



Cancer Genetics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Cancer Genetics's Net Margin for the fiscal year that ended in Dec. 2020 is calculated as

Net Margin=Net Income (A: Dec. 2020 )/Revenue (A: Dec. 2020 )
=-8.001/5.751
=-139.12 %

Cancer Genetics's Net Margin for the quarter that ended in Dec. 2020 is calculated as

Net Margin=Net Income (Q: Dec. 2020 )/Revenue (Q: Dec. 2020 )
=-3.769/1.311
=-287.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cancer Genetics  (NAS:CGIX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Cancer Genetics Net Margin % Related Terms

Thank you for viewing the detailed overview of Cancer Genetics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cancer Genetics (Cancer Genetics) Business Description

Traded in Other Exchanges
N/A
Address
201 Route 17 North, 2nd Floor, Meadows Office Complex, Rutherford, NJ, USA, 07070
Cancer Genetics Inc through its vivoPharm subsidiary offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies, and academic research centers. The company is focused on precision and translational medicine to drive drug discovery and novel therapies. Its subsidiary, vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. VivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.
Executives
Ralf Brandt officer: President, Discovery Services 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael Glenn Miles officer: Chief Financial Officer C/O CANCER GENETICS INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Franklyn G Prendergast director
Chaganti Raju S.k. director 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Edmund Cannon director 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Geoffrey E. Harris director 8 HARTLEY FARMS ROAD, MORRISTOWN NJ 07960
Howard Mcleod director 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
John Pappajohn director 1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
John A Roberts officer: Chief Executive Officer C/O CANCER GENETICS, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
William Lansing Finger officer: EVP Precision Medicine 201 ROUTE 17N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael Brian Mccartney officer: Chief Commercial Officer C/O CANCER GENETICS, INC., 201 ROUTE 17 N, 2ND FLOOR, RUTHERFORD NJ 07070
Rita Shaknovich officer: Chief Medical Officer C/O CANCER GENETICS, INC. 201 ROUTE 17N, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas F Widmann director 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070
Michael J. Welsh director UNIV. OF IOWA CARVER COLLEGE OF MEDICINE, DEPT. OF INTERNAL MEDICINE, 500 EMRB, IOWA CITY IA 52242
Igor Gitelman officer: Chief Accounting Officer 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070